BD Horizon™ BUV395 Mouse Anti-Human CD3 SK7 (also known as Leu-4) 100 Tests RUO 564001 from BD Biosciences

Published Figures

Register or Sign In to View Figures.

Journal for immunotherapy of cancer
October 01 2022

Fig 1: Enhanced LAG-3 shedding and expansion of circulating lymphocytes following FS118 treatment. Total serum concentration of soluble LAG-3 was measured using an ELISA. Samples for soluble receptors were taken prior to dosing on each cycle. (A) total serum concentration of sLAG-3 as measured by ELISA. Serum sLAG-3 was complexed with a saturating concentration of FS118, and the complex was captured with a non-competing anti-LAG-3 antibody clone 17B4 (Enzo life sciences) and detected with a non-competing anti-FS118 anti-idiotype antibody (Maine biotechnology services). (B). Total serum concentration of soluble PD-L1 was measured using electrochemiluminescence immunoassay (ECLIA). (B) soluble receptors were complexed with saturating amount of FS118, captured with a non-competing anti-PD-L1 antibody clone 130 021 (BioTechne) and detected with anti-FS118 anti-idiotype antibody (Maine biotechnology services). Max increase from baseline: 55 x (sLAG-3), 4.6 x (sPD-L1). (C) circulating T cells and NK cells 8 and 15 days post first dose, and on predose of cycle 3 day 1. Immunophenotyping was performed using flow cytometry on live fresh blood cells. The panel included antibodies to CD45 (HI30, BD biosciences, 563204), CD3 (SK7, BD biosciences, 564001), CD19 (HIB19, BioLegend, 302240), CD4 (SK3, BD biosciences, 563028), CD8 (SK1, BD biosciences, 564629), CD56 (HCD56, BioLegend, 318334) and Ki67 (20Raj1, eBioscience, 46-5699-42). Immune cell populations were defined as: CD4 T- cells (CD45+/CD3+/CD4+/CD8-/CD19-), CD8 T- cells (CD45+/CD3+/CD8+/CD4-/CD19-) and NK cells (CD45+/CD3-/CD19-/CD56+/CD16+/-). All values were reported as a percentage of total CD45+leucocytes, and only cell subsets with more than 50 cells were considered.
Register or Sign In to View Figures.

Journal for immunotherapy of cancer
October 01 2022

Fig 2: Enhanced LAG-3 shedding and expansion of circulating lymphocytes following FS118 treatment. Total serum concentration of soluble LAG-3 was measured using an ELISA. Samples for soluble receptors were taken prior to dosing on each cycle. (A) total serum concentration of sLAG-3 as measured by ELISA. Serum sLAG-3 was complexed with a saturating concentration of FS118, and the complex was captured with a non-competing anti-LAG-3 antibody clone 17B4 (Enzo life sciences) and detected with a non-competing anti-FS118 anti-idiotype antibody (Maine biotechnology services). (B). Total serum concentration of soluble PD-L1 was measured using electrochemiluminescence immunoassay (ECLIA). (B) soluble receptors were complexed with saturating amount of FS118, captured with a non-competing anti-PD-L1 antibody clone 130 021 (BioTechne) and detected with anti-FS118 anti-idiotype antibody (Maine biotechnology services). Max increase from baseline: 55 x (sLAG-3), 4.6 x (sPD-L1). (C) circulating T cells and NK cells 8 and 15 days post first dose, and on predose of cycle 3 day 1. Immunophenotyping was performed using flow cytometry on live fresh blood cells. The panel included antibodies to CD45 (HI30, BD biosciences, 563204), CD3 (SK7, BD biosciences, 564001), CD19 (HIB19, BioLegend, 302240), CD4 (SK3, BD biosciences, 563028), CD8 (SK1, BD biosciences, 564629), CD56 (HCD56, BioLegend, 318334) and Ki67 (20Raj1, eBioscience, 46-5699-42). Immune cell populations were defined as: CD4 T- cells (CD45+/CD3+/CD4+/CD8-/CD19-), CD8 T- cells (CD45+/CD3+/CD8+/CD4-/CD19-) and NK cells (CD45+/CD3-/CD19-/CD56+/CD16+/-). All values were reported as a percentage of total CD45+leucocytes, and only cell subsets with more than 50 cells were considered.
Register or Sign In to View Figures.

Journal for immunotherapy of cancer
October 01 2022

Fig 3: Enhanced LAG-3 shedding and expansion of circulating lymphocytes following FS118 treatment. Total serum concentration of soluble LAG-3 was measured using an ELISA. Samples for soluble receptors were taken prior to dosing on each cycle. (A) total serum concentration of sLAG-3 as measured by ELISA. Serum sLAG-3 was complexed with a saturating concentration of FS118, and the complex was captured with a non-competing anti-LAG-3 antibody clone 17B4 (Enzo life sciences) and detected with a non-competing anti-FS118 anti-idiotype antibody (Maine biotechnology services). (B). Total serum concentration of soluble PD-L1 was measured using electrochemiluminescence immunoassay (ECLIA). (B) soluble receptors were complexed with saturating amount of FS118, captured with a non-competing anti-PD-L1 antibody clone 130 021 (BioTechne) and detected with anti-FS118 anti-idiotype antibody (Maine biotechnology services). Max increase from baseline: 55 x (sLAG-3), 4.6 x (sPD-L1). (C) circulating T cells and NK cells 8 and 15 days post first dose, and on predose of cycle 3 day 1. Immunophenotyping was performed using flow cytometry on live fresh blood cells. The panel included antibodies to CD45 (HI30, BD biosciences, 563204), CD3 (SK7, BD biosciences, 564001), CD19 (HIB19, BioLegend, 302240), CD4 (SK3, BD biosciences, 563028), CD8 (SK1, BD biosciences, 564629), CD56 (HCD56, BioLegend, 318334) and Ki67 (20Raj1, eBioscience, 46-5699-42). Immune cell populations were defined as: CD4 T- cells (CD45+/CD3+/CD4+/CD8-/CD19-), CD8 T- cells (CD45+/CD3+/CD8+/CD4-/CD19-) and NK cells (CD45+/CD3-/CD19-/CD56+/CD16+/-). All values were reported as a percentage of total CD45+leucocytes, and only cell subsets with more than 50 cells were considered.
Register or Sign In to View Figures.

Journal for immunotherapy of cancer
October 01 2022

Fig 4: Enhanced LAG-3 shedding and expansion of circulating lymphocytes following FS118 treatment. Total serum concentration of soluble LAG-3 was measured using an ELISA. Samples for soluble receptors were taken prior to dosing on each cycle. (A) total serum concentration of sLAG-3 as measured by ELISA. Serum sLAG-3 was complexed with a saturating concentration of FS118, and the complex was captured with a non-competing anti-LAG-3 antibody clone 17B4 (Enzo life sciences) and detected with a non-competing anti-FS118 anti-idiotype antibody (Maine biotechnology services). (B). Total serum concentration of soluble PD-L1 was measured using electrochemiluminescence immunoassay (ECLIA). (B) soluble receptors were complexed with saturating amount of FS118, captured with a non-competing anti-PD-L1 antibody clone 130 021 (BioTechne) and detected with anti-FS118 anti-idiotype antibody (Maine biotechnology services). Max increase from baseline: 55 x (sLAG-3), 4.6 x (sPD-L1). (C) circulating T cells and NK cells 8 and 15 days post first dose, and on predose of cycle 3 day 1. Immunophenotyping was performed using flow cytometry on live fresh blood cells. The panel included antibodies to CD45 (HI30, BD biosciences, 563204), CD3 (SK7, BD biosciences, 564001), CD19 (HIB19, BioLegend, 302240), CD4 (SK3, BD biosciences, 563028), CD8 (SK1, BD biosciences, 564629), CD56 (HCD56, BioLegend, 318334) and Ki67 (20Raj1, eBioscience, 46-5699-42). Immune cell populations were defined as: CD4 T- cells (CD45+/CD3+/CD4+/CD8-/CD19-), CD8 T- cells (CD45+/CD3+/CD8+/CD4-/CD19-) and NK cells (CD45+/CD3-/CD19-/CD56+/CD16+/-). All values were reported as a percentage of total CD45+leucocytes, and only cell subsets with more than 50 cells were considered.
Register or Sign In to View Figures.

Journal for immunotherapy of cancer
October 01 2022

Fig 5: Enhanced LAG-3 shedding and expansion of circulating lymphocytes following FS118 treatment. Total serum concentration of soluble LAG-3 was measured using an ELISA. Samples for soluble receptors were taken prior to dosing on each cycle. (A) total serum concentration of sLAG-3 as measured by ELISA. Serum sLAG-3 was complexed with a saturating concentration of FS118, and the complex was captured with a non-competing anti-LAG-3 antibody clone 17B4 (Enzo life sciences) and detected with a non-competing anti-FS118 anti-idiotype antibody (Maine biotechnology services). (B). Total serum concentration of soluble PD-L1 was measured using electrochemiluminescence immunoassay (ECLIA). (B) soluble receptors were complexed with saturating amount of FS118, captured with a non-competing anti-PD-L1 antibody clone 130 021 (BioTechne) and detected with anti-FS118 anti-idiotype antibody (Maine biotechnology services). Max increase from baseline: 55 x (sLAG-3), 4.6 x (sPD-L1). (C) circulating T cells and NK cells 8 and 15 days post first dose, and on predose of cycle 3 day 1. Immunophenotyping was performed using flow cytometry on live fresh blood cells. The panel included antibodies to CD45 (HI30, BD biosciences, 563204), CD3 (SK7, BD biosciences, 564001), CD19 (HIB19, BioLegend, 302240), CD4 (SK3, BD biosciences, 563028), CD8 (SK1, BD biosciences, 564629), CD56 (HCD56, BioLegend, 318334) and Ki67 (20Raj1, eBioscience, 46-5699-42). Immune cell populations were defined as: CD4 T- cells (CD45+/CD3+/CD4+/CD8-/CD19-), CD8 T- cells (CD45+/CD3+/CD8+/CD4-/CD19-) and NK cells (CD45+/CD3-/CD19-/CD56+/CD16+/-). All values were reported as a percentage of total CD45+leucocytes, and only cell subsets with more than 50 cells were considered.

Description

The SK7 (Leu-4) monoclonal antibody specifically binds to the epsilon chain of the CD3 antigen/T-cell antigen receptor (TCR) complex. This complex is composed of at least six proteins that range in molecular weight from 20 to 30 kDa. The antigen recognized by CD3 antibodies is noncovalently associated with either α/β or γ/δ TCR (70 to 90 kDa). The CD3 antigen is present on 61% to 85% of normal peripheral blood lymphocytes 60% to 85% of thymocytes and on Purkinje cells in the cerebellum. The soluble form of this antibody has a mitogenic effect on most peripheral blood T lymphocytes, provided appropriate functional monocytes are present

Product Specs
ItemBD Horizon™ BUV395 Mouse Anti-Human CD3 SK7 (also known as Leu-4) 100 Tests RUO
CompanyBD Biosciences
Price $320.00Supplier Page View Company Product Page
Catalog Number564001
Quantity100 Tests
ApplicationsFlow cytometry
Conjugate/TagBUV395
ReactivityMouse
TargetCD3
IsotypeIgG1, κ
CloneSK7 (also known as Leu-4)
HostBALB/c
ClonalityMonoclonal
Regulatory StatusRUO
FormatAqueous buffered solution containing BSA and ≤0.09% sodium azide
ImmunogenHuman Thymocytes

Add to Compare List

BD Biosciences

155 North McCarthy Blvd

Milpitas, California 95035

United States

Company Profile

Website: www.bdbiosciences.com

(1) Protocol for analyzing immune cell infiltration in 3D pancreatic heterotypic spheroids composed of tumor cells and cancer-associated fibroblastsSTAR ProtocolsMarch 20, 2026Bessede Thomas, Vezzio-Vie Nadia, Freixinos Clara, Pirot Nelly, Bonnefoy Nathalie, Gongora Celine, Larbouret Christel, Gros Laurent[1/200]",Biolegend,302240/AB_2563442 "Anti-human CD3 BUV395, clone SK7 (mouse IgG1, κ) - dilution [1/200]",BD Bioscience,564001/AB_2744382 "Anti-human CD4 BUV496, clone RPAT4 (mouse IgG1, κ) - dilution [1/200]",BD Bioscience,741134/AB_2870714 "Anti-human

(2) Extensive Immunological and Inflammatory Perturbation Underpins the Respiratory Sequelae of Postacute COVID-19Open Forum Infectious DiseasesFebruary 5, 2026Gang Yang, Jinpeng Cao, Shidong Deng, Yingjiao Xia, Jun Zhao, Jian Qin, Xiaoyun Yang, Min Sun, Daxiang Chen, Ping Sun, et al.#566332) for viability assessment, followed by surface marker labeling using CD3-BUV395 (BD, 1:200, #564001, SK7), CD4-APC-H7 (BD, 1:150, #560158, RPA-T4), CD8-PerCP-Cy5.5 (BioLegend, 1:200, #344710, SK1), CCR7-APC

(3) Co-mapping clonal and transcriptional heterogeneity in somatic evolution via GoT-MultiCell GenomicsJanuary 14, 2026Minwoo Pak, Mirca S. Saurty-Seerunghen, Kellie Wise, Tsega-Ab Abera, Chhiring Lama, Neelang Parghi, Ted Kang, Xiaotian Sun, Qi Gao, Liming Bao, et al.BD Biosciences #341103); CD5 BV510/BV421 (BD Horizon #563381, BioLegend #364030); CD3 BUV395 (BD Biosciences #564001) and CD4-APC-A700 (BC #B10824). T-cells were isolated based on CD3 expression. CLL cells were distinguished

(4) ORAI1 mutation with mixed loss- and gain-of-function properties causes immunodeficiency and HLHJournal of Human ImmunityNovember 3, 2025Lucile Noyer, Priscilla S.-W. Yeung, Sascha Kahlfuss, Catherine Li Li Lai, Maxwell McDermott, Devisha Patel, Jun Yang, Yin-Hu Wang, Li Zhong, Peter Hsu, et al.harvesting. Cells were surface-stained with antibodies against CD3 (conjugated with BUV395, cat. no. 564001; BD Biosciences) and CD8 (BV510, cat. no. 563919; BD Biosciences) for 20 min at 4°C. Cells were fixed

(5) Divergent cytokine and transcriptional signatures control functional T follicular helper cell heterogeneityNature immunologyOctober 1, 2025Dalit L, Tan CW, Sheikh AA, Munnings R, Howson LJ, Alvarado C, Hussain T, Zaini A, Cooper L, Kirn A, et al.612749); anti-CD4 (1:20 dilution; clone SK3; BD; cat. no. 341095); anti-CD3 (1:20; clone SK7; BD; cat. no. 564001); anti-CD8 (1:20 dilution; clone SK1; BD; cat. no. 664530); anti-CD45RA (1:50 dilution; clone HI100;

(6) Preclinical evaluation of folate receptor-alpha chimeric antigen receptor T cells (FOLR1-CART) exhibit highly efficient anti-tumor activity against osteosarcomaCancer Research CommunicationsSeptember 8, 2025Michelle Choe, Danielle Kirkey, Isabel Lira, Grace Hawkins, Melia Blankenfeld, Sarah Menashe, Rhonda E. Ries, Brianna Wrightson, Christina Root, Cyd N. McKay, et al.anti–CD45-BUV805 [BD Biosciences (RRID: SCR_013311) 612891], anti–CD3-BUV395 [BD Biosciences (RRID: SCR_013311) 564001], anti–CD4-BV605 [BD Biosciences (RRID: SCR_013311) 562658], anti–CD8-BV711 [BD Biosciences (RRID: SCR_013311)

(7) Preclinical Evaluation of Folate Receptor-α Chimeric Antigen Receptor T Cells Exhibits Highly Efficient Antitumor Activity against OsteosarcomaCancer Res CommunSeptember 1, 2025Michelle Choe, Danielle Kirkey, Isabel Lira, Grace Hawkins, Melia Blankenfeld, Sarah Menashe, Rhonda E. Ries, Brianna Wrightson, Christina Root, Cyd N. McKay, et al.anti–CD45-BUV805 [BD Biosciences (RRID: SCR_013311) 612891], anti–CD3-BUV395 [BD Biosciences (RRID: SCR_013311) 564001], anti–CD4-BV605 [BD Biosciences (RRID: SCR_013311) 562658], anti–CD8-BV711 [BD Biosciences (RRID: SCR_013311)

(8) Mast cells boost anti-tumor potency of MAIT cells via inflammasome-dependent secretion of IL-18Nat CommunJuly 2, 2025Fanfan Fan, Jun Wang, Kun Liu, Shiyue Zhang, Jian Gao, Xiongfei Li, Jiaqiang Ma, Yue Zhao, Teng Li, Han Su, et al.Biolegend, 361110; IL-18BP, MCE, HY-P7211). The following antibodies were used: anti-CD3D BUV395 (BD, Cat#564001), anti-CD4 BV570 (Biolegend, Cat#300534), anti-CD8 AF700 (BD, Cat#557945), anti-CD25 APC (Biolegend,

(9) Second generation CD2-targeting LFA-3 fusion protein SBT115301 to restore immune homeostasis in autoimmune diseaseiScienceMay 16, 2025Herve Lebrec, John Bui, Jonathan M. Clingan, Jason Do, Jason Dubovsky, Leonard Dragone, Ekaterina Gibiansky, Wing Yu Lam, Katherine Matsuda, Lauren Mihalcik, et al.,BD Biosciences,"Cat#555919, RRID: AB_396220" "Mouse Anti-Human CD3, Brilliant UV 395, Clone SK7",BD Biosciences,"Cat#564001, RRID: AB_2744382" "Mouse Anti-Human CD4, Brilliant UV 496, Clone SK3",BD Biosciences,"Cat#612936,

(10) T cell memory response to MPXV infection exhibits greater effector function and migratory potential compared to MVA-BN vaccinationNat CommunMay 10, 2025Ji-Li Chen, Beibei Wang, Yongxu Lu, Elie Antoun, Olivia Bird, Philip G. Drennan, Zixi Yin, Guihai Liu, Xuan Yao, Maya Pidoux, et al.BioLegend, 302242) dumping markers; then with the surface markers CD3-BUV395 (1:50, BD Biosciences, 564001), CD45RA-APC-H7 (1:33, BD Biosciences, 560674), CD8-PerCP.Cy5.5 (1:33, BD Biosciences, 565310), CD27-BUV496

(11) Single-cell RNA sequencing reveals the pro-inflammatory roles of liver-resident Th1-like cells in primary biliary cholangitisNature communicationsOctober 7, 2024Jin C, Jiang P, Zhang Z, Han Y, Wen X, Zheng L, Kuang W, Lian J, Yu G, Qian X, et al.human FACS analysis included: APC-H7 Mouse anti-Human CD45(560178,BD); BUV395 Mouse Anti-Human CD3(564001,BD); FITC Mouse Anti-Human TCR αβ(555547,BD); BV480 Mouse Anti-Human CD4(566104,BD); BUV737 Mouse Anti-Human CD25

(12) Systemic dysregulation and molecular insights into poor influenza vaccine response in the aging populationScience advancesSeptember 27, 2024Kumar S, Zoodsma M, Nguyen N, Pedroso R, Trittel S, Riese P, Botey-Bataller J, Zhou L, Alaswad A, Arshad H, et al.stained for flow cytometric analysis using the following antibodies: CD3 (BUV395, SK7, catalog no. 564001, dilution 1:200; BD, Franklin Lakes, New Jersey, USA) and CD56 (BV785, 5.1H11, catalog no. 362550, dilution

(13) Mucosal‐associated invariant T cells modulate innate immune cells and inhibit colon cancer growthScandinavian Journal of ImmunologySeptember 1, 2024Olivia J. Cheng, Eric J. Lebish, Owen Jensen, Damian Jacenik, Shubhanshi Trivedi, Jackson G. Cacioppo, Jeffrey Aubé, Ellen J. Beswick, Daniel T. Leung810,Biolegend,304076 Anti-CD45RO,UCHL1,BUV737,BD Biosciences,748368 Anti-CD3,SK7,BUV395,BD Biosciences,564001 Anti-CD4,SK3,BUV496,BD Biosciences,612937 Anti-CD8,RPA-T8,BV570,Biolegend,301038 MR1–5OPRU,NA,PE,NIH

(14) Initial COVID-19 severity influenced by SARS-CoV-2-specific T cells imprints T-cell memory and inversely affects reinfectionSignal Transduction and Targeted TherapyMay 29, 2024Gang Yang, Jinpeng Cao, Jian Qin, Xinyue Mei, Shidong Deng, Yingjiao Xia, Jun Zhao, Junxiang Wang, Tao Luan, Daxiang Chen, et al.discrimination marker Live/Dead-FVS440 (BD, Cat# 566332); surface-stained antibodies: anti-CD3-BUV395 (BD, Cat# 564001, 1:200, clone SK7), anti-CD4-APC-H7 (BD 560158, 1:150, clone RPA-T4), anti-CD8-PerCy5.5 (BioLegend,

(15) Predictive biomarkers and initial analysis of maternal immune alterations in postpartum preeclampsia reveal an immune-driven pathologyFrontiers in ImmunologyApril 30, 2024Camille Couture, Marie-Eve Brien, Jade Rechtzigel, SuYun Ling, Cecilia Ledezma-Soto, Gilberto Duran Bishop, Ines Boufaied, Dorothée Dal Soglio, Evelyne Rey, Serge McGraw, et al.antibody cocktail [with catalog numbers; concentration] including 5μl of each of the following: (anti-CD3 [564001; 0.1mg/ml], anti-CD4 [557871; 0.2mg/ml], anti-CD8 [560662; 0.05mg/ml], anti-CD14 [557923; 0.2mg/ml],

(16) Fat-to-blood recirculation of partially dysfunctional PD-1+CD4 Tconv cells is associated with dysglycemia in human obesityiScienceMarch 15, 2024Anna Giovenzana, Eugenia Bezzecchi, Anita Bichisecchi, Sara Cardellini, Francesca Ragogna, Federica Pedica, Federica Invernizzi, Luigi Di Filippo, Valentina Tomajer, Francesca Aleotti, et al.RRID:AB_2819021 APC-Cy7 anti-human CD25,Biolegend,Cat#356122; RRID:AB_2562488 BUV395 anti-human CD3,BD,Cat#564001; RRID:AB_2744382 PerCP anti-human CD3,Biolegend,Cat#344814; RRID:AB_10639948 BUV805 anti-human CD4,BD,Cat#612887;

(17) PREX1 improves homeostatic proliferation to maintain a naive CD4+ T cell compartment in older ageJCI insightFebruary 8, 2024Zhang H, Okuyama H, Jain A, Jadhav RR, Wu B, Sturmlechner I, Morales J, Ohtsuki S, Weyand CM, Goronzy JJ.experiments. Flow cytometry. The following antibodies were used for phenotypic characterization: anti-CD3 (BD, 564001), anti-CD4 (BioLegend, 344642), anti-CCR7 (BioLegend, 353225), anti-CD45RA (BD, 555488), anti-CD62L

(18) MVA-based vaccine candidates encoding the native or prefusion-stabilized SARS-CoV-2 spike reveal differential immunogenicity in humansnpj VaccinesJanuary 26, 2024Leonie Mayer, Leonie M. Weskamm, Anahita Fathi, Maya Kono, Jasmin Heidepriem, Verena Krähling, Sibylle C. Mellinghoff, My Linh Ly, Monika Friedrich, Svenja Hardtke, et al.controls, respectively. Cells were then washed and stained with an antibody mix of anti-CD3-BUV395 (1:100; #564001; BD Biosciences), anti-CD4-AF700 (1:50; #300526; BioLegend), anti-CD19-BV510 (1:100; #302242; BioLegend),

(19) Virus infection pattern imprinted and diversified the differentiation of T-cell memory in transcription and functionFrontiers in ImmunologyJanuary 9, 2024Yuan Wang, Xinyue Mei, Zhengfang Lin, Xiaoyun Yang, Jinpeng Cao, Jiaying Zhong, Junxiang Wang, Li Cheng, Zhongfang Wangat room temperature with the following antibodies: anti-CD3-BUV395 (BD Bioscience, clone SK7, Cat# 564001), anti-CD4-BV786 (BioLegend, clone RPA-T4, Cat# 300554), anti-CD8-BV605 (BioLegend, clone RPA-T8, Cat#

(20) Impact of Mycobacterium tuberculosis Glycolipids on the CD4+ T Cell-Macrophage Immunological SynapseJournal of immunology (Baltimore, Md. : 1950)November 1, 2023Mwebaza I, Shaw R, Li Q, Fletcher S, Achkar JM, Harding CV, Carpenter SM, Boom WH.anti-CD27-APC, anti-IFN-γ-PE, anti-TNF-α-AF700, anti-IL-2-BV650, anti-CD25-BUV395, anti-CD69-BV421 (Cat#564001, 563833, 564324, 565931, 563589, 565775, 562933, 565419, 558664, 559326, 557996, 563467, 567484, 562883,

Write a Review

(1)

5/5/2017Good Antibody For Human Lung CD3 Cells Rebecca GuyerOur lab studies various markers on lymphocytes extracted from human tissue samples. We need good markers to identify T cells specifically. We chose this antibody because it was very low spillover ... Read Review

Journal for immunotherapy of cancer

Journal for immunotherapy of cancer

Journal for immunotherapy of cancer

Journal for immunotherapy of cancer

Journal for immunotherapy of cancer

BD Horizon™ BUV395 Mouse Anti-Human CD3 SK7 (also known as Leu-4) 100 Tests RUO from BD Biosciences

Description

BD Biosciences

Citations (41)

Reviews

BD Horizon™ BUV395 Mouse Anti-Human CD3 SK7 (also known as Leu-4) 100 Tests RUO from BD Biosciences

About Biocompare

Advertise with Us

Specialized Search Tools

Site Map